GlobeNewswire·Nov 26, 2025, 1:45 AM ET

Nyxoah's Genio® Therapy Receives Significant 2026 Medicare Reimbursement Increases Under Final CMS Rule

NYXH

Nyxoah's Genio® therapy received significant 2026 Medicare reimbursement increases under the final CMS Hospital Outpatient Prospective Payment System (HOPPS) and Ambulatory Surgery Center (ASC) Rule.
The CPT Code 64568 for Genio hypoglossal nerve stimulation implants was assigned to New Technology Ambulatory Payment Classification (APC) 1580.
Effective January 1, 2026, Hospital Outpatient Department reimbursement for CPT 64568 will rise to approximately $45,000, a 48% increase from 2025 levels.
Ambulatory Surgery Center facility reimbursement for CPT 64568 will increase to $42,373, reflecting a 58% increase compared to 2025.
These reimbursement updates apply uniformly to all procedures billed under CPT 64568, including Genio® procedures.
The rate increases are expected to strengthen hospital & ASC economics, support broader adoption, increase procedural throughput, & expand across Medicare-heavy institutions.
Nyxoah CEO Olivier Taelman stated the decision reinforces the recognition of hypoglossal nerve stimulation as a high-value therapy for obstructive sleep apnea.
The single-incision nature of Genio® is well suited for the ASC environment, & the payment increase creates new opportunities for site-of-service diversification.
Genio® is a leadless, battery-free hypoglossal neurostimulation therapy approved by the FDA in August 2025 for adult patients with moderate to severe obstructive sleep apnea.
Nyxoah received CE Mark approval in 2019, with later indications expanded to include Complete Concentric Collapse patients.